Advertisement
U.S. markets open in 1 hour 40 minutes
  • S&P Futures

    5,190.50
    -24.25 (-0.47%)
     
  • Dow Futures

    39,127.00
    -96.00 (-0.24%)
     
  • Nasdaq Futures

    18,109.75
    -121.75 (-0.67%)
     
  • Russell 2000 Futures

    2,040.20
    -9.60 (-0.47%)
     
  • Crude Oil

    82.72
    0.00 (0.00%)
     
  • Gold

    2,158.10
    -6.20 (-0.29%)
     
  • Silver

    25.15
    -0.12 (-0.47%)
     
  • EUR/USD

    1.0854
    -0.0022 (-0.21%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.84
    +0.51 (+3.56%)
     
  • GBP/USD

    1.2693
    -0.0036 (-0.28%)
     
  • USD/JPY

    150.4190
    +1.3210 (+0.89%)
     
  • Bitcoin USD

    63,100.79
    -5,129.61 (-7.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,700.46
    -22.09 (-0.29%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Institutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI)

To get a sense of who is truly in control of Puma Biotechnology, Inc. (NASDAQ:PBYI), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 45% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.

Let's delve deeper into each type of owner of Puma Biotechnology, beginning with the chart below.

Check out our latest analysis for Puma Biotechnology

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Puma Biotechnology?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Puma Biotechnology does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Puma Biotechnology, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 15% of Puma Biotechnology. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. With a 15% stake, CEO Alan Auerbach is the largest shareholder. With 9.1% and 7.8% of the shares outstanding respectively, Camber Capital Management LP and The Vanguard Group, Inc. are the second and third largest shareholders.

On further inspection, we found that more than half the company's shares are owned by the top 8 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Puma Biotechnology

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

It seems insiders own a significant proportion of Puma Biotechnology, Inc.. It has a market capitalization of just US$228m, and insiders have US$35m worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 25% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Puma Biotechnology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 5 warning signs with Puma Biotechnology (at least 2 which don't sit too well with us) , and understanding them should be part of your investment process.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Advertisement